Here's Auscanns response to my email questioning their continues...

Here's Auscanns response to my email questioning their continues decline in SP and lack of direction since new CEO

Thank you for your email.It was Canopy’s decision to sell and who they sold to - AusCann was notinvolved in Canopy’s decision to sell and the price they sold at, or whothey sold to.The broader listed medicinal cannabis sector has underperformed in the last12 months.AusCann has undergone a transformation in the last 12 months with theappointment of a new CEO, optimisation of its product supply chain, and afocus on the pharmaceutical product development.The changing market landscape has been discussed by AusCann’s new CEO andhas vindicated the Company’s decision to focus its business strategy onPharmaceutical product development where it can continue to build itscompetitive advantage and differentiation – and realise longer termsustained value for shareholders.AusCann continues to work with business partners at the operational level,and is working to generate clinical evidence that will reduce risk andcreate value that would make the Company and the sector more attractive tolarge pharma.AusCann is well advanced with this and will be releasing its hard-shellcapsules for clinical trials by the end of this year.You may have also seen our recently released investor presentationhttps://clients3.weblink.com.au/pdf/AC8/02145631.pdf and investor webinarfrom 25th September (https://clients3.weblink.com.au/pdf/AC8/02152275.pdf)which outlines our strategy, along with the business and growth outlook.We appreciate your continued support as a shareholder.Kind RegardsThe AusCann Team